[TRUST study: general practice relevant data on erlotinib in NSCLC].
D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D017327:Clinical Trials, Phase IV as Topic; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use* / Q000633:toxicity; D011799:Quinazolines / Q000627:therapeutic use* / Q000633:toxicity; D016019:Survival Analysis
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride
TRUST-Studie: Praxisrelevante Daten zu Erlotinib beim NSCLC.